Pembrolizumab (unresectable advanced and metastatic cancer); Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® Page last updated: 14 November 2025 Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF 820KB) Public Summary Document (PSD) July 2025 PBAC Meeting - (Word 181KB)